Conference Coverage

MONARCH 3: Abemaciclib plus AI boosts PFS in HR+/HER2- breast cancer

Publish date: September 19, 2017

 

AT ESMO 2017

Pages

Recommended Reading

Use of Pap smears, mammography on the decline
MDedge ObGyn
FDA approves neratinib for extended adjuvant treatment of HER2+ breast cancer
MDedge ObGyn
Annual mammograms from age 40 linked with greatest reductions in mortality
MDedge ObGyn
2017 Update on female sexual dysfunction
MDedge ObGyn
FDA expands approval of fulvestrant for HR+/HER2– advanced breast cancer
MDedge ObGyn
Focus on lifestyle to manage menopause symptoms after breast cancer
MDedge ObGyn
FDA clears first 2D mammography device with patient-controlled compression
MDedge ObGyn
Ten-year outcomes support skipping axillary lymph node dissection with positive sentinel nodes
MDedge ObGyn
Surgeons strongly influenced chances of contralateral prophylactic mastectomy
MDedge ObGyn
LORELEI sings praises of neoadjuvant taselisib/letrozole in ER+/HER2– breast cancer
MDedge ObGyn